Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated autologous G-CSF mobilised CD133+ bone marrow stem cell infusions in cirrhosis
2009-010335-41Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenograstim in Cirrhosis and alpha-1 antitrypsin deficiency (AATD) (3 arms), sponsored by University of Birmingham. Primary endpoint: Change in MELD score from baseline to Day 90. Started Jun 2009; status: completed.
02
Drugs
lenograstim
03
Conditions
Cirrhosisalpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2009-010335-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010335-41.